ArticleInternational journal of oncology2022

Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.

Huihui Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.